Guidelines support GLP-1 use for primary prevention in type 2 diabetes with CVD/high CVD risk and for secondary prevention alongside metformin independent of HbA1c; weight-loss-only benefit is unestablished. SHOW MORE.
You know, the glucagon-like peptide-1 receptor agonist medications (GLP-1s) have captured everyones imagination. I was the first person to ever give a GLP-1 to a person with diabetes back in the late 1980s.
:max_bytes(150000):strip_icc()/HDC-GettyImages-2195485788-299e147644524b339a084114355dff83.jpg)
Furthermore, visual representations like the one above help us fully grasp the concept of Glp-1 Peptides And Diabetes Prevention.
GLP-1 drugs in obese patients with type 2 diabetes and sleep apnea are associated with an 8% reduced need for CPAP therapy, a 32% lower risk of all-cause mortality, and a 10% reduction in hospitalization compared to SGLT2 inhibitors.
The first and only GIP and GLP-1 receptor agonist indicated to improve glycemic control in adults with type 2 diabetes. GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1; APLD=anonymized patient level data. Mounjaro works differently1.
They screened 100 peptides, including GLP-1, for their ability to activate lab-grown neuronal cells. As expected, the GLP-1 peptide had a robust effect on the neuronal cells, increasing their activity threefold over control cells.
